Cheliensisin A inhibits EGF-induced cell transformation with stabilization of p53 protein via a hydrogen peroxide/Chk1-dependent axis

Cancer Prevention Research

Volumn 6, Issue 9, 2013, Pages 949-958

  Zhang, Jingjie ^a   Gao, Guangxun ^a   Chen, Liang ^a   Deng, Xu ^b   Li, Jingxia ^a   Yu, Yonghui ^a   Zhang, Dongyun ^a   Li, Fei ^a   Zhang, Min ^a   Zhao, Qinshi ^b   Huang, Chuanshu ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KUNMING INSTITUTE OF BOTANY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CHECKPOINT KINASE 1; CHELIENSISIN A; EPIDERMAL GROWTH FACTOR; HYDROGEN PEROXIDE; LACTONE DERIVATIVE; MESSENGER RNA; MUTANT PROTEIN; PROTEIN P53; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL TRANSFORMATION; CHEMOPROPHYLAXIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; GONIOTHALAMUS; GONIOTHALAMUS CHELIENSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; TREATMENT DURATION;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; EPIDERMAL GROWTH FACTOR; EPIDERMIS; EPOXY COMPOUNDS; FLOW CYTOMETRY; HUMANS; HYDROGEN PEROXIDE; MICE; OXIDANTS; PHOSPHORYLATION; PROTEIN KINASES; PROTEIN STABILITY; PROTEOLYSIS; PYRONES; REACTIVE OXYGEN SPECIES; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84883766290     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-13-0097     Document Type: Article

References (44)

1. Kelloff GJ, Crowell JA, Steele VE, Lubet RA, Malone WA, Boone CW, et al. Progress in cancer chemoprevention: development of diet-derived chemopreventive agents. J Nutr 2000;130:467S-71S. (Pubitemid 30073775)
2. Patterson SL, Colbert Maresso K, Hawk E. Cancer chemoprevention: successes and failures. Clin Chem 2013;59:94-101.
3. Sporn MB, Suh N. Chemoprevention of cancer. Carcinogenesis 2000;21:525-30. (Pubitemid 30137938)
4. Wiart C. Lead compounds from medicinal plants for the treatment of cancer. Elsevier Inc., London, UK. 1st. ed. 2013.
5. Surh YJ. Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer 2003;3:768-80.
6. Li CM, Mu Q, Sun HD, Xu B, Tang WD, Zheng HL, et al. A new anticancer constituent of Goniothalamus cheliensis. Acta Bot Yunnan 1998;20:102-4.
7. Zhong L, Li CM, Hao XJ, Lou LG. Induction of leukemia cell apoptosis by cheliensisin A involves down-regulation of Bcl-2 expression. Acta Pharmacol Sin 2005;26:623-8. (Pubitemid 40676176)
8. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53. (Pubitemid 21917115)
9. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323-31. (Pubitemid 27131374)
10. Schmitt CA, Fridman JS, Yang M, Baranov E, Hoffman RM, Lowe SW. Dissecting p53 tumor suppressor functions in vivo. Cancer Cell 2002;1:289-98. (Pubitemid 41039153)
11. Sengupta S, Harris CC. p53: traffic cop at the crossroads of DNA repair and recombination. Nat Rev Mol Cell Biol 2005;6:44-55. (Pubitemid 40064898)
12. Fuster JJ, Sanz-González SM, Moll UM, Andrés V. Classic and novel roles of p53: prospects for anticancer therapy. Trends Mol Med 2007;13:192-9. (Pubitemid 46687126)
13. Shangary S, Wang S. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. Annu Rev Pharmacol Toxicol 2009;49:223-41.
14. She QB, Bode AM, Ma WY, Chen NY, Dong Z. Resveratrol-induced activation of p53 and apoptosis is mediated by extracellular-signal-regulated protein kinases and p38 kinase. Cancer Res 2001;61:1604-10. (Pubitemid 34292594)
15. Zhang J, Ouyang W, Li J, Zhang D, Yu Y, Wang Y, et al. Suberoylanilide hydroxamic acid (SAHA) inhibits EGF-induced cell transformation via reduction of cyclin D1 mRNA stability. Toxicol Appl Pharmacol 2012;263:218-24.
16. Zhang Z, Chen F, Huang C, Shi X. Vanadate induces G2/M phase arrest in p53-deficient mouse embryo fibroblasts. J Environ Pathol Toxicol Oncol 2002;21:223-31. (Pubitemid 35257749)
17. Leung-Pineda V, Ryan CE, Piwnica-Worms H. Phosphorylation of Chk1 by ATR is antagonized by a Chk1-regulated protein phosphatase 2A circuit. Mol Cell Biol 2006;26:7529-38. (Pubitemid 44547703)
18. Rodríguez AM, Carrico PM, Mazurkiewicz JE, Meléndez JA. Mitochondrial or cytosolic catalase reverses the MnSOD-dependent inhibition of proliferation by enhancing respiratory chain activity, net ATP production, and decreasing the steady state levels of H(2)O(2). Free Radic Biol Med 2000;29:801-13.
19. Ding J, Zhang X, Li J, Song L, Ouyang W, Zhang D, et al. Nickel compounds render anti-apoptotic effect to human bronchial epithelial Beas-2B cells by induction of cyclooxygenase-2 through an IKKbeta/p65-dependent and IKKalpha- and p50-independent pathway. J Biol Chem 2006;281:39022-32. (Pubitemid 46041861)
20. Wang S, Shi X. Mechanisms of Cr(VI)-induced p53 activation: the role of phosphorylation, mdm2 and ERK. Carcinogenesis 2001;22:757-62. (Pubitemid 32447924)
21. Zhang D, Li J, Gao J, Huang C. c-Jun/AP-1 pathway-mediated cyclin D1 expression participates in low dose arsenite-induced transformation in mouse epidermal JB6 Cl41 cells. Toxicol Appl Pharmacol 2009;235:18-24.
22. Li F, Wang H, Li L, Huang C, Lin J, Zhu G, et al. Superoxide plays critical roles in electrotaxis of fibrosarcoma cells via activation of ERK and reorganization of the cytoskeleton. Free Radic Biol Med 2012;52:1888-96.
23. Huang C, Li J, Ke Q, Leonard SS, Jiang BH, Zhong XS, et al. Ultraviolet-induced phosphorylation of p70(S6K) at Thr(389) and Thr(421)/Ser (424) involves hydrogen peroxide and mammalian target of rapamycin but not Akt and atypical protein kinase C. Cancer Res 2002;62:5689-97. (Pubitemid 35204723)
24. Boulares AH, Yakovlev AG, Ivanova V, Stoica BA, Wang G, Iyer S, et al. Role of poly(ADP-ribose) polymerase (PARP) cleavage in apoptosis. Caspase 3-resistant PARP mutant increases rates of apoptosis in transfected cells. J Biol Chem 1999;274:22932-40.
25. Schuler M, Bossy-Wetzel E, Goldstein JC, Fitzgerald P, Green DR. p53 induces apoptosis by caspase activation through mitochondrial cytochrome c release. J Biol Chem 2000;275:7337-42. (Pubitemid 30146286)
26. Appella E, Anderson CW. Post-translational modifications and activation of p53 by genotoxic stresses. Eur J Biochem 2001;268:2764-72. (Pubitemid 32862957)
27. Rojas M, Yao S, Lin YZ. Controlling epidermal growth factor (EGF)-stimulated Ras activation in intact cells by a cell-permeable peptide mimicking phosphorylated EGF receptor. J Biol Chem 1996;271:27456-61. (Pubitemid 26367305)
28. Shieh SY, Ikeda M, Taya Y, Prives C. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 1997;91:325-34. (Pubitemid 27467963)
29. Zhou BP, Liao Y, Xia W, Zou Y, Spohn B, Hung MC. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat Cell Biol 2001;3:973-82. (Pubitemid 34428742)
30. Ou YH, Chung PH, Sun TP, Shieh SY. p53 C-terminal phosphorylation by CHK1 and CHK2 participates in the regulation of DNA-damage-induced C-terminal acetylation. Mol Biol Cell 2005;16:1684-95.
31. Abraham RT. Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev 2001;15:2177-96. (Pubitemid 32843830)
32. Kulkarni A, Das KC. Differential roles of ATR and ATM in p53, Chk1, and histone H2AX phosphorylation in response to hyperoxia: ATR-dependent ATM activation. Am J Physiol Lung Cell Mol Physiol 2008;294:L998-L1006.
33. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000;408:307-10.
34. Chène P. Inhibiting the p53-MDM2 interaction: an important target for cancer therapy. Nat Rev Cancer 2003;3:102-9. (Pubitemid 37328877)
35. Hursting SD, Perkins SN, Phang JM, Barrett JC. Diet and cancer prevention studies in p53-deficient mice. J Nutr 2001;131:3092S-4S. (Pubitemid 33070786)
36. Bai L, Zhu W. p53: structure, function and therapeutic applications. J Cancer Mol 2006;2:141-53.
37. Wolf D, Rotter V. Major deletions in the gene encoding the p53 tumor antigen cause lack of p53 expression in HL-60 cells. Proc Natl Acad Sci U S A 1985;82:790-4. (Pubitemid 15142764)
38. Shieh SY, Ahn J, Tamai K, Taya Y, Prives C. The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. Genes Dev 2000;14:289-300. (Pubitemid 30106484)
39. Barker GF, Manzo ND, Cotich KL, Shone RK, Waxman AB. DNA damage induced by hyperoxia: quantitation and correlation with lung injury. Am J Respir Cell Mol Biol 2006;35:277-88. (Pubitemid 44353395)
40. Cacciuttolo MA, Trinh L, Lumpkin JA, Rao G. Hyperoxia induces DNA damage in mammalian cells. Free Radic Biol Med 1993;14:267-76. (Pubitemid 23066367)
41. Simon HU, Haj-Yehia A, Levi-Schaffer F. Role of reactive oxygen species (ROS) in apoptosis induction. Apoptosis 2000;5:415-8. (Pubitemid 32162623)
42. Pérez-Galán P, Roué G, Villamor N, Montserrat E, Campo E, Colomer D. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood 2006;107:257-64. (Pubitemid 43053550)
43. Shen SC, Lee WR, Yang LY, Tsai HH, Yang LL, Chen YC. Quercetin enhancement of arsenic-induced apoptosis via stimulating ROS-dependent p53 protein ubiquitination in human HaCaT keratinocytes. Exp Dermatol 2012;21:370-5
44. Shimizu T, Numata T, Okada Y. A role of reactive oxygen species in apoptotic activation of volume-sensitive Cl(-) channel. Proc Natl Acad Sci U S A 2004;101:6770-3. (Pubitemid 38586049)